Evaluating Dapagliflozin’s Impact on Bone Health in Lupus Nephritis: Insights from a Double-Blind, Placebo-Controlled Trial

Highlight

• Dapagliflozin treatment in lupus nephritis patients did not significantly alter bone turnover markers over one year.
• Quantitative computed tomography showed modest improvement in lumbar spine L3 bone density, but overall bone mineral density decline was nonsignificant after adjustment.
• The study supports the renal and cardiovascular benefits of SGLT2 inhibitors without evident harm to bone health in this vulnerable population.

Background